MARKET NEWS

Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated With COVID-19 Severity
Onconova Therapeutics Announces Topline Results From Pivotal Phase 3 INSPIRE Trial
EDAP Announces Approval for Phase 2 Study 
BioAge Discovers Key Pathway & Identifies Promising Phase 2-Ready Drug to Treat & Reverse Immune Aging, a Root Cause of COVID-19 Morbidity & Mortality in Older Patients
AbbVie Submits Regulatory Application to FDA for RINVOQ

  FEATURED EDITORIAL

  COMPANY PROFILE

Foster Delivery Science focuses on GMP and Formulation development Hot Melt Extrusion, applying our expertise using twin screw extruders not only for traditional solubility enhancement techniques, but to create local and long term Drug Delivery Implant and film solutions.  As extrusion is a continuous process by nature, melt granulation programs are an obvious interest for lifecycle management and new drug development. Using the industry range of FDA acceptable polymers, we can create permanent and bio-absorbable implants to deliver drugs immediately or over a desired time period.  These implants can be micro implants like ophthalmic applications or macro such as intravaginal rings. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors

Rain Therapeutics Inc. recently announced the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of….

Cancer Genetics & StemoniX Sign Definitive Agreement to Merge

Cancer Genetics & StemoniX Sign Definitive Agreement to Merge

Cancer Genetics, Inc. and StemoniX, Inc. recently announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and….

Catalent Signs Agreement With AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine

Catalent Signs Agreement With AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine

Catalent, Inc. recently announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 9 – Injection Devices
September 16 – Lyophilization Manufacturing